Physical chemical considerations of lipid-based oral drug delivery - Solid lipid nanoparticles

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 21, Issue 1, 2004, Pages 1-19

  Bummer, Paul M ^a  

^a University of Kentucky   (United States)

Author keywords

Lipid aggregate; Lipid solubility; Nanoparticle; Physical properties

Indexed keywords

SOLID LIPID NANOPARTICLE; DRUG; DRUG CARRIER; LIPID;

CHEMICAL ANALYSIS; DRUG DELIVERY SYSTEM; DRUG RELEASE; PEYER PATCH; PHYSICAL CHEMISTRY; REVIEW; SOLUBILITY; CHEMICAL MODEL; CHEMISTRY; CRYSTALLIZATION; DRUG STABILITY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; CHEMISTRY, PHARMACEUTICAL; CHEMISTRY, PHYSICAL; CRYSTALLIZATION; DRUG CARRIERS; DRUG STABILITY; LIPIDS; MODELS, CHEMICAL; PHARMACEUTICAL PREPARATIONS; SOLUBILITY;

EID: 3042586026     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevtherdrugcarriersyst.v21.10     Document Type: Review

References (55)

1. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413-420.
2. Cavalli R, Bargoni A, Podio V, Muntoni, E, Zara, GP, Gasco, MR. Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J Pharm Sci 2002; 92:1085-1094.
3. Malmsten M. Surface chemistry in pharmacy. In: Holmberg K, editor. Handbook of Applied Surface and Colloid Chemistry. New York: Wiley, 2002.
4. Israelachvilli J. Theory of self assembly of hydrocarbon amphiphiles into micelles and bilayers. J Chem Soc Farad Trans II 1976; 77:1525-1567.
5. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Del Rev 2002; 54:631-651.
6. Vauthier C, Dubernet C, Chauvierre C, Brigger I, Couvreur P. Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. J Control Rel 2003; 93:151-160.
7. Kabanov AV, Batrakova EV, Alakhov V Yu. An essential relationship between ATP depletion and chemosensitizing activity of Pluronic® block copolymers. J Control Release 2003; 91:75-83.
8. Batrakova EV, Li S, Alakhov V Yu, Elmquist WF, Miller DW, Kabanov AV. Sensitization of cells overexpressing multidrug-resistant proteins by Pluronic P85. Pharm Res 2003; 20:1581-1590.
9. Manthena V, Varma S, Ashokraj Y, Dey CS, Panchagnula R. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res 2003; 48:347-359.
10. Brooks KR, To K, Moore Joshi MB, Conlon DH, Herndon JE, D'Amico TA, Harpole DH. Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection. Ann Thorac Surg 2003; 76:187-193.
11. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharma Biopharm 2000; 50:161-77.
12. Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and self-microemulsifying drug delivery systems. Eur J Pharm Sci 2002; S11:S93-98.
13. Constantinides PP, Scalart JP. Formulation and physical characterization of water-in-oil microemulsions containing long-versus medium-chain glycerides. Int J Pharm 1997; 158:57-69.
14. Koynova R, Caffrey M. An index of lipid phase diagrams. Chem Phys Lipids 2000; 115:107-219.
15. Taha M.O, Al-Ghazawi M, Abu-Amara H Khalil E. Development of quantitative structure-property relationship models for pseudoternary microemulsions formulated with nonionic surfactants and cosurfactants: application of data mining and molecular modeling. Eur J Pharm Sci 2002; 15:461-478.
16. Kreilgaard M, Pedersen EJ, Jaroszewski JW. NMR characterization and transdermal drug delivery potential of microemulsion systems. J Control Release 2000; 69: 421-433.
17. Zografi G, Zerenda I. Surface activity of phenothiazines at the air-solution interface. Biochem Pharmacol 1966; 15: 591-598.
18. Malcolm C, Lawrence MJ. A comparison of the incorporation of model steroids into non-ionic micellar and microemulsion systems. J Pharm Pharmacol 1993; 45: 141-143.
19. Testard F, Zemb Th. Excess of solubilization of lindane in nonionic surfactant micelles and microemulsions. Langmuir 1998; 14:3175-3181.
20. Testard F, Zemb Th. Excess of solubilization and curvature in nonionic microemulsions. J Colloid Interfac Sci 1999; 219:11-19.
21. Yamaoka Y, Roberts RD, Stella VJ. Low-melting phenytoin prodrugs as alternative oral delivery modes for phenytoin: a model for other high-melting sparingly water-soluble drugs. J Pharm Sci 1983; 72:400-405.
22. Akaho E, Iga K, Kraal J, Hussain A. Solubility behavior of phenolic compounds in hexane-ethyl acetate, hexane-ethyl myristate and hexane-ethyl pivalate cosolvent systems. J Pharm Sci 1981; 70:1225-1228.
23. Inagi T, Muramatsu T, Hidetaka N, Terada H. Influence of vehicle composition on the penetration of indomethacin through guinea pig skin. Chem Pharm Bull 1981; 29:1708-1713.
24. Anderson BA, Marra MT. Chemical and related factors controlling lipid solubility. J Gattefosse 1999; 92:11-18
25. Abraham MH. Hydrogen Bonding 31. Construction of a scale of solute effectiveness or summation of hydrogen bonding basicity. J Phys Org Chem 1993; 6:660-684.
26. Larsen DB, Parshad H, Fredholt K, Larsen C. Characteristics of drug substances in oily solutions. Drug release rate, partitioning and solubility. Int J Pharm 2002; 232; 107-117.
27. Fredholt K, Larsen, DH, Larsen C. Modification of in vitro drug release rate from oily parenteral depots using a formulation approach. Eur J Pharm Sci 2000; 11:231-237.
28. Banerjee S. Bioconcentration factors and lipid solubility. Environ Sci Tech 1991; 25: 536-539.
29. Land LM, Li P, Bummer PM. The effect of water on the solubility of steroid drugs in medium and long chain triglycerides. AAPS Pharm Sci Abstract W4082 2002.
30. Westesen K. Novel lipid-based colloidal dispersions as potential drug administration systems-expectations and reality. Colloid Polym Sci 2000; 278:608-618.
31. Zimmermann E, Müller RH, Mäder K. Influence of different parameters on reconstitution of lyophilized SLN. Int J Pharm 2000; 196:211-213.
32. Mei Z, Chen H, Weng T, Yang Y, Yang X. Solid lipid nanoparticle and microemulsion for topical delivery of triptolide. Eur J Pharmaceut Biopharm 2003; 56:189-196.
33. Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm 2002; 238:241-245.
34. Hsu C-H, Cui Z, Mumper RJ, Jay M. Preparation and characterization of novel coenzyme Q10 nanoparticles engineered from microemulsion precursors. AAPS PharmSciTech 2003; 4: article 32.
35. García-Fuentes M, Torres D, Alonso MJ. Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules. Coll Surf B 2002; 27:159-168
36. zur Mühlen A, Mehnert W. Drug release and release mechanisms of prednisolone loaded solid lipid nanospheres. Pharmazie 1998; 53:552-555.
37. Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Del Rev 2002; 154 (Suppl 1):S131-155.
38. Cui Z, Mumper RJ. Coating of cationized protein on engineered nanoparticles results in enhanced immune responses. Int J Pharm 2002; 238:229-239.
39. Bummer PM, Koppenol S. Chemical and physical considerations in protein and peptide stability. In McNally E, editor. Protein Formulation and Delivery. New York: Dekker, 2000.
40. Gref R, Lück P, Quellec P, Marchand M, Dellacherie E, Harnisch S, Blunk T, Müller RH. "Stealth" corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Coll Surf B 2000; 18:301-314.
41. Tobío M, Sánchez A, Vila A, Soriano I, Evora C, Vila-Jato JL, Alonso MJ. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Coll Surf B 2000; 18:315-323.
42. zur Mühlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm 1998; 45: 149-155.
43. Kreuter J. Peroral administration of nanoparticles. Adv Drug Deliv Rev 1991; 7: 71-86.
44. Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State and Mater Sci 2002; 6:319-327.
45. Vila A, Sánchez A, Tobío M, Calvo P, Alonso MJ. Design of biodegradable particles for protein delivery. J Control Release 2002; 78:15-24.
46. Janes KA, Calvo P, Alonso MJ. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Del Rev 2001; 47:83-97.
47. Jenning V, Mäder K, Gohla SH. Solid lipid nanoparticles (SLN™) based on binary mixtures of liquid and solid lipids: a 1H-NMR study. Int J Pharm 2000; 205:15-21.
48. Siekmann B, Westesen K. Thermoanalysis of the recrystallization process of melt-homogenized glyceride nanoparticles. Coll Surf B 1994; 3:159-175.
49. Westesen K, Bunjes H, Koch MHJ. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Control Release 1997; 48:223-236.
50. Staggers JA, Hernell O, Stafford RJ, Carey MC. Physical-chemical behavior of dietary and biliary lipids during intestinal lipid systems patterned after aqueous duodenal contents of healthy adult human beings digestion and absorption. Biochem 1990; 29: 2028-2040.
51. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 2000; 50:161-177.
52. Zimmerman E, Muller RH. Electrolyte- and pH-stabilities of aqueous solid lipid nanoparticle (SLN™) dispersions in artificial gastrointestinal media. Eur J Pharm Biopharm 2001; 52:203-210.
53. Feitas C, Muller RH. Stability determination of solid lipid nanoparticles in aqueous dispersion after addition of electrolyte. J Microencap 1999; 16:59-71.
54. Holstborg J, Pedersen BV, Krog N, Olesen SK. Physical properties of diglycerol esters in relation to rheology and stability of protein-stabilized emulsions. Coll Surf B 1999; 12:383-390.
55. Washington C, Davies SS. Aging effects in parenteral fat emulsions; the role of fatty acids. Int J Pharm 1987; 39:33-37.